MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson’s disease

R. Kumar, A. Kanojia (Darbhanga, India)

Meeting: 2023 International Congress

Abstract Number: 595

Keywords: 1-Methyl-4-phenylpyridinium (MPP+), Drug-induced parkinsonism(DIP), Neuroprotective agents

Category: Drug-Induced Movement Disorders

Objective: Aim of study was to elucidate the pharmacological Invivo and invitro effects and mechanisms of action of

RT in experimental models of PD.

Background: The MPTP-induced PD model is characterized by chronic inflammation, oxidative stress and loss of the dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc). Resveratrol (RT) improves cognition and limits neuroinflammation in the brain. However, the beneficial effects of RT in ameliorating Parkinson’s disease (PD) remain unknown.

Method: We utilized SH-SY5Y cells exposed to RT (20μM) against 1-methyl-4-phenylpyridinium iodide (MPP+ ) as an in vitro PD model. Cell viability and apoptosis were analyzed via the MTT assay and flow cytometry. Mitochondrial morphology, apoptotic markers such as B-cell lymphoma-2 (Bcl-2) and Bcl-2-associated X protein (Bax), mitochondrial respiratory capacity and ROS were measured by a mitochondrial tracker, a Seahorse analyzer and a MitoSOX-Red dye.

For in vivo PD model, behavioral tests, Nissl staining and immunohistochemistry were used to evaluate the protection of RT (50 mg/kg body weigh). The levels of tyrosine hydroxylase (TH), cAMP response element-binding protein (CREB) and cytokines levels ( IL-1β, IL-6 and TNF-α) were analyzed by by Western blotting, RT-PCR and quantitative PCR analysis.

Results: RT decreased MPP+ -induced apoptosis in SH-SY5Y cells and human dopaminergic neurons. RT also increased mitochondrial respiratory capacity, decreased ROS production and restored mitochondrial morphology. RT reversed the MPP+ -induced reductions of phosphorylated CREB, PGC-1α, and TH, while the protective effects were blocked by the PKA inhibitor H-89 and via PGC-1α siRNA. In mice treated with MPTP, RT significantly improved motor functions. Importantly, RT prevented both dopaminergic neuronal loss and the reduction of phosphorylated CREB and glial activation, decreasing the levels of IL-1β, IL-6 and TNF-α, as well as their respective receptors in the SNpc of MPTP-treated mice.

Conclusion: RT may be a promising neuroprotective agent for the treatment of neurodegenerative disorders such as Parkinson’s disease. Results suggest that RT may play a neuroprotective role via modulating the mitochondrial-mediated signaling and CREB pathway in MPTP/MPP+-induced PD.

To cite this abstract in AMA style:

R. Kumar, A. Kanojia. Pharmacological Invivo and invitro potential of resveratrol in experimental rat models of Parkinson’s disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/pharmacological-invivo-and-invitro-potential-of-resveratrol-in-experimental-rat-models-of-parkinsons-disease/. Accessed May 9, 2025.
  • Tweet
  • Email
  • Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/pharmacological-invivo-and-invitro-potential-of-resveratrol-in-experimental-rat-models-of-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • The hardest symptoms that bother patients with Parkinson's disease
  • The clinical effects of mucuna and green tea in combination with levodopa-benserazide in advanced Parkinson's disease: Experience from a case report
  • To be or not to bupropion: a drug-induced parkinsonism?
  • #25822 (not found)
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Restless Leg Syndrome After Propranolol Intake: A Single Case
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley